Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Goal and EQ504 Program in Immune-Mediated Ailments Transcript

Operator

Good afternoon, and welcome to the Equillium Bio Digital KOL Occasion. [Operator Instructions] As a reminder, this name is being recorded, and a replay will probably be made accessible on the Equillium web site following the conclusion of the occasion.

I might now like to show the decision over to your host, Bruce Metal, Chief Government Officer at Equillium Bio. Please go forward, Bruce.

Bruce Metal
Co-Founder, CEO & Director

Thanks very a lot. Good morning and/or good afternoon to everyone for becoming a member of at this time. We significantly admire you taking your time to study extra in regards to the aryl hydrocarbon receptor and our EQ504 program. We’ll, in the course of the course of the day on the firm aspect, be making doubtlessly some forward-looking statements, so we refer you to our disclaimer right here.

We’re very happy at this time to have Dr. Francisco Quintana and Dr. Brian Feagan, who’re specialists of their fields masking immune-mediated issues and gastroenterology, respectively. We will probably be discussing an outline of the aryl hydrocarbon receptor and why that is such a compelling drug goal throughout a variety of potential immune-mediated ailments. Clearly, our focus as an organization with EQ504 will probably be directing this program initially into the therapy of ulcerative colitis, the place regardless of an infinite quantity of funding in lots of accepted medication throughout totally different modalities, there stays a really excessive unmet medical